Market news

Activist campaigns tend to surface when a stock’s performance no longer matches its story, and The Cooper Companies, Inc. (NASDAQ:COO) is a case in point. In mid-September 2026, Jana Partners, which built its stake in the contact lens maker roughly a year ago. It began pushing Cooper to replace CEO Albert White and its board […]

Citing “chronic underperformance,” Jana Partners is calling for new leadership and for the company to evaluate the sale of its fertility and medical device assets.

For almost nine months, The Cooper Companies, Inc. (NASDAQ:COO) has been trying to sell its CooperSurgical unit. But on September 9, 2026, the company ended the strategic review it had launched in December 2025 and decided to keep the business. The reason is that the bids received were not in shareholders’ interest and reflected a […]

As Cooper Companies has lagged behind its industry peers over the past year, Wall Street analysts maintain a cautious outlook on its prospects.

In September 2026, The Cooper Companies completed a broad strategic review, ultimately deciding to retain CooperSurgical after assessing potential sale offers, while also outlining revised capital allocation plans and operational initiatives for CooperVision and CooperSurgical. The Board cited temporary factors such as a new competitor in non-hormonal IUDs and the impact of recent fertility litigation settlements as reasons for a perceived valuation gap that made selling CooperSurgical less...

Lawrence Erik Kurzius, Director, on September 16, 2026, executed a purchase for 10,000 shares in Coo

Walter M Rosebrough Jr, Director, on September 11, 2026, executed a purchase for 10,000 shares in Co

Tipranks Press Release.

The Cooper Companies, Inc. (NASDAQ:COO) cut its fiscal 2026 profit and revenue forecasts after weaker-than-expected demand for contact lenses weighed on its CooperVision business. The company now expects adjusted earnings of $4.51–$4.55 per share, down from its previous forecast of $4.58–$4.66, while revenue guidance was reduced to $4.23–$4.25 billion from $4.29–$4.32 billion. Third-quarter revenue came in […]

Detailed price information for Cooper Companies (COO-Q) from The Globe and Mail including charting and trades.

The Cooper Companies Inc. (NASDAQ:COO), a leading medical device company, announced its third quarter fiscal 2026 results on September 9. Topline went up 1% to $1.066 billion in comparison with the same quarter last year, which also included 1% organic growth. The company posted quarterly adjusted diluted EPS of $1.15, which represented a 4% jump […]

Cooper won't sell its Surgical arm, and it was forced to cut forward guidance. Wall Street didn't like that.

Shares of Cooper Cos. are pacing the S&P 500’s decliners Thursday after the maker of medical devices reported mixed results, issued soft guidance and wrapped up a strategic review without plans to seek a deal.

Investors hammered Cooper Companies on Thursday after the medtech's fiscal third-quarter sales lagged expectations.

Moby summary of The Cooper Companies, Inc.'s Q3 2026 earnings call

According to TheFly, Baird flagged the company’s increasingly challenging margin leverage heading into fiscal 2027, saying it limits COO stock's near-term appeal

The Cooper Companies (COO) delivered earnings and revenue surprises of +3.60% and -2.97%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock?

CooperCompanies keeps CooperSurgical after review, citing valuation gap; boosts buyback to $3B. Read more here.

Here are some of the names making headlines in extended trading.